Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
SER
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Market Cap
Shares Outstanding
Share in Float
Dividende
Earning Date
No Data
Price Target
Average Volume
Beta
Range
Industry
Website
Sector
Earnings Growth
YoY
Current
Estimates
Sales Growth
YoY
Current
Estimates
Return on Equity
QoQ
Institutionnal Ownership
QoQ
Q3.23
N/A
-5.01
vs -2.26
Q4.23
N/A
-3.20
vs -3.04
Q1.24
N/A
-3.38
vs NA
Q2.24
+464%
0.51
vs -0.14
Q3.24
+103%
0.13
vs -5.01
Q4.24
N/A
-0.27
vs -3.20
Q1.25
N/A
-0.49
vs -3.38
Q2.25
N/A
-0.66
vs 0.51
Q3.25
N/A
-0.53
vs 0.13
Q4.25
N/A
-0.47
vs -0.27
Q3.23
+644%
67K vs 9K
Q4.23
+38238%
3.1M vs 8K
Q1.24
-50%
5K vs 10K
Q2.24
+467%
51K vs 9K
Q3.24
-79%
14K vs 67K
Q4.24
-100%
-14000.00 vs 3.1M
Q1.25
-100%
NA vs 5K
Q2.25
+155%
130K vs 51K
Q3.25
+839%
131.5K vs 14K
Q4.25
+1049%
132.9K vs -14000
Q1.23
+16%
0.16
vs 0.16
Q2.23
+8%
0.08
vs 0.16
Q3.23
-64%
-0.64
vs 0.08
Q4.23
-84%
-0.84
vs -0.64
Q1.24
+219%
2.19
vs -0.84
Q2.24
-32%
-0.32
vs 2.19
Q3.24
-10%
-0.10
vs -0.32
Q4.24
-427%
-4.27
vs -0.10
Q1.25
-283%
-2.83
vs -4.27
Q2.25
-358%
-3.58
vs -2.83
Q1.23
NA
NA
vs NA
NA
Q2.23
NA
NA
vs NA
NA
Q3.23
NA
NA
vs NA
NA
Q4.23
NA
NA
vs NA
NA
Q1.24
13
13
vs NA
NA
Q2.24
21
21
vs 13
62%
Q3.24
24
24
vs 21
14%
Q4.24
25
25
vs 24
4%
Q1.25
25
25
vs 25
NA
Q2.25
23
23
vs 25
-8%
Quote Panel
Key Metrics
Forecast
22%2026-Revenue
17%2026-EPS
-22%2026-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
H.C. Wainwright
initialisePrevious: Not converted
2025-07-14
Now: Buy
globenewswire.com
7 hours ago
globenewswire.com
15 hours ago
globenewswire.com
16 hours ago
Relative Strength
SER
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How SER compares to sector?
SER
-4x
Serina Therapeutics, Inc., a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson's disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson's disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc. was founded in 2006 and is based in Huntsville, Alabama.
NYSE
Unprofitable
Unprofitable
Relative Strenght
14
Volume Buzz
-96%
Earning Acce
No
Dist 52w H.
36%